IPHA

Innate Pharma SA

Healthcare · Biotechnology

$237.59 sample

-1.40 (-0.59%) 1D

Market cap

$200.8B

Price as of

2026-10-03

Latest filing

8-K · 2026-09-08

Alerts

8

Price$237.59 +12.26% 3M daily closessample

247.77205.61

2026-07-072026-07-292026-08-202026-09-102026-10-02

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Sep 25INSInsider sell: 10% owner
Sep 16INSInsider buy: 10% owner
Sep 08SEC8-K filed: material event
Sep 02SECForm 144 filed
Aug 25INSInsider buy: EVP, Operations
Aug 20SEC10-Q filed
Aug 14INSInsider buy: General Counsel
Aug 06INSInsider buy: Chief Financial Officer

Sign up to see the real IPHA record →

Company facts

SEC EDGAR registration

Name: Innate Pharma SA
Sector: Healthcare
Industry: Biotechnology
Smart-money score: +37sample, -100 to +100
Reporting currency: USD

Who is positioning in IPHA

sample

Insiders: 24 insider transactions over 90 days, net selling, $631.7M
Congress: 5 members traded over 90 days
Institutions · 13F: 27 funds hold $2.2B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$10.7B +15.1% y/y

Q4 2024Q3 2026

Inventory$6.6B +9.5% y/y

Q4 2024Q3 2026

Accounts receivable$4.9B +7.5% y/y

Q4 2024Q3 2026

Total debt$12.5B +10.2% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $199.4B -10.9% 3M
Sample peer B: $141.2B +1.1% 3M
Sample peer C: $96.7B -4.0% 3M
Sample peer D: $45.3B -10.6% 3M
Sample peer E: $143.9B +4.4% 3M